Comparison of two intravenous anesthetic infusion regimens for alfaxalone in cats

Pypendop, Bruno H.; Ranasinghe, M. G.; Pasloske, Kirby

doi:10.1016/j.vaa.2018.03.003

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assuming that effects correlate with plasma drug concentration, a loading dose and single constant rate infusion would therefore fail to result in a stable effect in most clinical scenarios. Similar considerations were experimentally confirmed for alfaxalone in cats (Pypendop et al, 2018).…”

Section: Discussionsupporting

confidence: 80%

Pharmacokinetics of butorphanol in male neutered cats anesthetized with isoflurane

Pypendop

Shilo‐Benjamini

2021

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

Opioids are commonly administered during anesthesia to provide analgesia, blunt autonomic responses to nociception and reduce anesthetic requirements (KuKanich & Wiese, 2015). Few drugs in this class have received regulatory approval for use in cats. Butorphanol, an agonist of kappa opioid receptors and antagonist of mu opioid receptors, is approved for use in cats by the Federal Drug Administration of the United States for the relief of pain caused by minor or major trauma or associated with surgical procedures. In addition, because formulations for animal use are commercially available, butorphanol has been less affected than other opioids by the common drug shortages in the United States and is more likely to be available to veterinarians in countries in which the use in animals of drug formulations for humans is restricted or prohibited. To the authors' knowledge, the disposition of butorphanol in anesthetized cats has not been reported. The aim

show abstract

Section: Discussionsupporting

confidence: 80%

Pharmacokinetics of butorphanol in male neutered cats anesthetized with isoflurane

Pypendop

Shilo‐Benjamini

2021

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the Dexdomitor ® -buprenorphine-Alfaxan ® protocol, there was marked increase in the blood glucose concentration. This could be due to the potential side effects of dexmedetomidine which include polyuria and interference with insulin production, contributing to hyperglycemia [10].…”

Section: Discussionmentioning

confidence: 99%

“…The most common side effect is respiratory depression. A new formulation of alfaxalone has been employed producing light anaesthesia lasting between 30 minutes in rabbits and ferrets, to few hours in cats and dogs, depending on the dose employed, and fast recovery with minimal or limited cardiovascular effects [6][7][8][9][10][11]. However, a lack of analgesia was observed, and analgesic support should be provided in painful procedures [12].…”

Section: Alfaxalone Is Commonly Used In Veterinarymentioning

confidence: 99%

Anaesthetic and Cardiopulmonary Effects of Dexamedetomidine, Buprenorphine, Dexmedetomidine – Buprenorphine on Alfaxalone in Adult Rabbits – A comparative Study

Sogebi

Cliff

2020

NIDOC-ASRT

View full text Add to dashboard Cite

“…Pypendop et al. have infused the RD0327 formulation in cats for 240 min on two occasions (Pypendop, Ranasinghe, & Pasloske, ,). In both studies, all cats survived and there were no adverse events.…”

Section: Discussionmentioning

confidence: 99%

The bioequivalence of a single intravenous administration of the anesthetic alfaxalone in cyclodextrin versus alfaxalone in cyclodextrin plus preservatives in cats

Pasloske

Ranasinghe

Sauer

et al. 2018

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

To demonstrate the bioequivalence of alfaxalone in cyclodextrin (Reference Product) to a formulation of alfaxalone in cyclodextrin also containing the preservatives ethanol, chlorocresol, and benzethonium chloride (Test Product) when administered for the purpose of inducing anesthesia in the cat. Blinded, single-dose, randomized, two-period, twosequence, cross-over bioequivalence study with a 7-day washout period between treatments. Twenty-four (12 neutered males and 12 intact females), healthy, adult cats weighing 4.1±0.9 kg. Cats were administered 5 mg/kg IV of alfaxalone in the Reference or Test Product using a randomized cross-over design. One-milliliter venous blood samples were collected at predetermined time points to 12 hr after drug administration to determine alfaxalone plasma concentration over time. Alfaxalone concentrations were determined by a validated analytical testing method using HPLC-MS/MS. Plasma profiles of alfaxalone concentration against time were analyzed by noncompartmental analysis. The pivotal variables for bioequivalence were AUC last and C max . Equivalence was achieved if the 90% confidence interval for AUC last and C max fell into the asymmetric ±20% interval

show abstract

Comparison of two intravenous anesthetic infusion regimens for alfaxalone in cats

Cited by 7 publications

References 21 publications

Pharmacokinetics of butorphanol in male neutered cats anesthetized with isoflurane

Pharmacokinetics of butorphanol in male neutered cats anesthetized with isoflurane

Anaesthetic and Cardiopulmonary Effects of Dexamedetomidine, Buprenorphine, Dexmedetomidine – Buprenorphine on Alfaxalone in Adult Rabbits – A comparative Study

The bioequivalence of a single intravenous administration of the anesthetic alfaxalone in cyclodextrin versus alfaxalone in cyclodextrin plus preservatives in cats

Contact Info

Product

Resources

About